ADC quantification to classify patients candidate to receive bevacizumab treatment for recurrent glioblastoma.
Background: Recurrent high-grade gliomas progressing after surgery and temozolomide plus radiation therapy have traditionally been treated using antiangiogenic drugs as the first-line therapy. Since the phase 3 EORTC 26101 trial showed no significant benefit of administering antiangiogenic drugs, th...
| Publicado en: | Acta Radiologica Vol. 61; no. 3; pp. 404 - 414 |
|---|---|
| Autores principales: | , , , , , |
| Formato: | Journal Article |
| Publicado: |
Sage Publications Inc.
Mar2020
|
| Acceso en línea: | Ver este registro en EBSCOhost |